Global Blood Therapeutics, Inc.
- Jurisdiction
United States - LEI
549300U4G0QKK99GRT15 - ISIN
US37890U1088 (GBT )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
3
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). Read full profile
Stock price
Fundamentals
- Net revenue
€200.32M - Gross margin
98.1% - EBIT
-€253.67M - EBIT margin
-126.6% - Net income
-€278.38M - Net margin
-139.0%
Statement period: - (published )
Dividends
No dividend payouts